

The Efficient Stereoselective Synthesis of (2*S*,3*R*,4*S*,5*S*,6*S*,11*E*)-3-Amino-6-methyl-12-(4-methoxyphenyl)-2,4,5-trihydroxydodec-11-enoic Acid (AMMTD), a Component of Microsclerodermins of Marine Sponge Origin, as Its Protected Form

Shigekazu Sasaki,^a Yasumasa Hamada,^{b,*} and Takayuki Shioiri ^{a,*}

^a Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya 467-8603, JAPAN

^b Faculty of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba 263-8522, JAPAN

Received 29 January 1999; accepted 19 February 1999

Abstract: The title acid, a component of microsclerodermins of marine sponge origin having five consecutive stereogenic centers, was efficiently synthesized as its protected form **1** from the alcohol **5** utilizing the stereoselective addition of anisole to the acetylenic triple bond and the anti-aldol reaction as key steps. © 1999 Elsevier Science Ltd. All rights reserved.

Keywords: Marine metabolites, Amino acid and derivatives, Aldol reactions, Addition reactions

Microsclerodermins A and B were isolated from the lithistid marine sponge *Microscleroderma* sp. collected near New Caledonia by Faulkner and co-workers.¹ They exhibit antifungal activities especially against *Candida albicans*, and proved to be 23-membered cyclic hexapeptides containing four unusual amino acid components, as shown in Fig. 1. The structure of AMMTD, (2*S*,3*R*,4*S*,5*S*,6*S*,11*E*)-3-amino-6-methyl-12-(4-methoxyphenyl)-2,4,5-trihydroxydodec-11-enoic acid, is quite unique and features five consecutive stereogenic centers. As a continuation of our studies on the synthesis of biologically active aquatic natural products,² we have attempted the total synthesis of this unique cyclic peptides.³ We have already reported the stereoselective synthesis of the core building block **1'** for AMMTD.⁴ We herein wish to report the efficient stereoselective synthesis of the AMMTD derivative **1** using a methodology different from the former one.






Fig. 1

Our retrosynthetic analysis is illustrated in Scheme 1. The protected derivative **1** of AMMTD, the target of this synthesis, would be constructed by the anti-aldol reaction of the aldehyde **2** with the ketone **3** and then azidation as the key steps. The aldehyde **2** would be derived from the alkyne **4** through the palladium catalyzed addition reaction of anisole. The obvious starting material for the synthesis of **4** would be the acetonide alcohol **5**, previously prepared from the ester **6** in 10 steps.⁴




The acetonide alcohol **5** was first silylated with *tert*-butyldimethylsilyl chloride (TBSCl) and then catalytically hydrogenated over palladium-carbon to yield the alcohol **7**. Conversion of the alcohol **7** to the corresponding iodide was accomplished with iodine-imidazole-triphenylphosphine. The iodide produced was treated with lithium trimethylsilyl(TMS) acetylide to give the TMS-alkyne **8**, from which the TMS group was removed with potassium carbonate in methanol to furnish the alkyne **9**. Hydrozirconation of **9** followed by the addition of *p*-iodoanisole using bis(triphenylphosphine)palladium chloride-diisobutylaluminum hydride (DIBAL) according to Negishi's protocol⁵ afforded the anisyl-(*E*)-alkene **10** in 78% yield. Removal of the TBS group from **10** with tetra-*n*-butylammonium fluoride (TBAF) yielded the alcohol **11**, which was oxidized under the Swern conditions. The resulting aldehyde underwent the anti-aldol reaction with the ketone **12** to give the keto alcohol **13** as a single isomer using dicyclohexylboron chloride in the presence of dimethylethylamine.⁶ The ketone **12** was prepared from methyl (*R*)-lactate **14**, which was converted to the TBS Weinreb amide **15** by treatment with *N*-methoxy-*N*-methylaminoaluminum and then TBSCl-imidazole. The reaction of the Weinreb amide **15** with *p*-methoxybenzyl(MPM) oxymethyl tributyl stannane-butyllithium followed by TBAF afforded the keto alcohol **16**, whose hydroxyl group was protected with benzoyl chloride to give the ketone **12**, as shown in Scheme 3.

The keto alcohol **13** was reduced with lithium borohydride to give the triol. The *vic*-diol part of the triol was cleaved with sodium periodate, followed by reduction of the resulting aldehyde with sodium borohydride to give the desired alcohol **17** in 83% yield in two steps. After protection of the primary alcohol with pivaloyl chloride (PivCl), conversion of the secondary alcohol to the azide was achieved in 60% yield by sequential treatment with triflic anhydride (Tf₂O) and then tetra-*n*-butylammonium azide. Reduction of the obtained azide **18** with lithium aluminum hydride followed by the Boc (*tert*-butoxycarbonyl) protection afforded the *N*-Boc alcohol **19** in 62% yield (2 steps). The final step for the synthesis of the AMMTD derivative **1** was the conversion of the primary hydroxyl function to the ester one, which was achieved in three steps : (1) the



Scheme 2



Scheme 3

Parikh-Doering oxidation, (2) the oxidation with sodium chlorite, and (3) the methyl esterification to give the desired AMMTD derivative **1**.


Thus, we have accomplished the synthesis of the AMMTD derivative **1**, a requisite building block for the total synthesis of microsclerodermins, by the stereoselective construction of five consecutive stereogenic centers. We are now actively conducting the synthetic studies of microsclerodermins.

Acknowledgment : This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan.

References and Notes

* Fax : +81-52-834-4172 ; e-mail : shioiri@phar.nagoya-cu.ac.jp

- (a) Bewley, C. A. ; Debitus, C. ; Faulkner, D. J. *J. Am. Chem. Soc.* **1994**, *116*, 7631-7636. (b) Recently, microsclerodermins C, D, and E were isolated from two species of lithistid sponges from the Visayan Islands, Philippines. See Schmidt, E. W. ; Faulkner, D. J. *Tetrahedron* **1998**, *54*, 3043-3056.
- For our recent work in this area, see Yokokawa, F. ; Shioiri, T. *J. Org. Chem.* **1998**, *63*, 8638-8639.
- A part of this work was presented at the First International Peptide Symposium held in Kyoto, Japan, on November 30-December 5, 1997 and at the 35th Japanese Peptide Symposium held in Saga, Japan, on October 7-9, 1998.
- Sasaki, S. ; Hamada, Y. ; Shioiri, T. *Tetrahedron Lett.* **1997**, *38*, 3013-3016.
- Negishi, E. ; Takahashi, T. ; Baba, S. ; Horn, D. E. V. ; Okukado, N. *J. Am. Chem. Soc.* **1987**, *109*, 2393-2401.
- Paterson, I. ; Wallace, D. J. ; Velazquez, S. M. *Tetrahedron Lett.* **1994**, *35*, 9083-9086 and 9087-9090, and references cited therein. The absolute configurations at the newly formed stereogenic centers were confirmed as follows: **17** was converted to **20**; analogously, *ent*-**20** was obtained from diethyl L-tartrate. ¹H-NMR and [α]_D of **20** and *ent*-**20** unambiguously revealed the absolute configurations.



- 1**, a colorless oil: [α]_D²⁷ -8.29° (c 0.82, CHCl₃); IR ν_{max}^{neat} cm⁻¹ 3445, 1755, 1743, 1615, 1504, 1456, 1304, 1211; ¹H-NMR (CDCl₃) δ 0.87 (3H, d, *J* = 6.6 Hz, CH₃CH) 1.11-1.57 (7H, m, CH(CH₂)₃) 1.37 (9H, s, Me₃C) 1.41 (3H, s, Me₂C) 1.43 (3H, s, Me₂C) 2.16-2.18 (2H, m, CH₂CH=CH) 3.72 (3H, s, CO₂Me) 3.78 (3H, s, OMe) 3.79 (3H, s, OMe) 3.72-3.84 (1H, m, CH₃CHCH) 3.84-3.93 (1H, m, CHOMPM) 4.12-4.19 (1H, m, CH₃CHCHCH) 4.41 (2H, s, OCH₂Ar) 4.70 (1H, d, *J* = 10.9 Hz, CHNH₂Boc) 4.88 (1H, d, *J* = 10.2 Hz, NH) 6.06 (1H, dt, *J* = 6.6, 15.8 Hz, CH=CHAr) 6.34 (1H, d, *J* = 15.8 Hz, CH=CHAr) 6.81-6.89 (4H, m, MeOAr (o)) 7.19-7.32 (4H, m, MeOAr (m)); ¹³C-NMR (CDCl₃) δ 16.58, 26.61, 27.72, 27.81, 28.17, 29.68, 30.89, 32.94, 36.12, 52.00, 55.25, 56.01, 72.81, 76.53, 77.09, 79.64, 84.54, 109.18, 113.72, 113.87, 126.95, 128.84, 129.11, 129.41, 129.93, 130.76, 155.27, 158.59, 159.47, 171.58; HRMS (EI) *m/z* calcd. for C₃₇H₅₃NO₉: 655.3737. Found: 655.3720; Anal. calcd for C₃₇H₅₃NO₉: C, 67.76; H, 8.15; N, 2.14. Found: C, 67.49; H, 8.07; N, 2.12.